# Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

> **NCT00203372** · PHASE2 · COMPLETED · sponsor: **Translational Oncology Research International** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab 7.5 and TAC
- **DRUG:** Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
- **DRUG:** Bevacizumab 15 and TAC
- **DRUG:** Placebo 15 and TAC

## Key facts

- **NCT ID:** NCT00203372
- **Lead sponsor:** Translational Oncology Research International
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2012-06
- **Final completion:** —
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203372, "Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00203372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*